Barclays Portfolio holdings
Barclays is a British universal bank whose roots go back to 1690, when the Quakers John Freame and Thomas Gould started a goldsmith banking business in London. The Barclays name came into the business in 1736, when James Barclay, son-in-law of founder John Freame, became a partner. Barclays launched the UK's first credit card, Barclaycard, in 1966, and in 1967 put the world's first cash machine in a branch in Enfield. In 2008 Barclays bought the North American operations of Lehman Brothers, and in 2009 it sold its Barclays Global Investors unit, home of the iShares ETFs, to BlackRock. It runs five divisions: UK consumer banking, UK corporate banking, private banking and wealth management, an investment bank and a US consumer bank.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$17.5B |
| 2 |
NVIDIA
NVDA
|
+$2.7B |
| 3 |
Intel
INTC
|
+$1.98B |
| 4 |
Broadcom
AVGO
|
+$1.46B |
| 5 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$1.11B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI Emerging Markets ETF
EEM
|
+$35.8B |
| 2 |
Apple
AAPL
|
+$1.83B |
| 3 |
Invesco QQQ Trust
QQQ
|
+$913M |
| 4 |
Microsoft
MSFT
|
+$856M |
| 5 |
Bank of America
BAC
|
+$792M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 49.47% |
| 2 | Technology | 19.84% |
| 3 | Consumer Discretionary | 7.61% |
| 4 | Financials | 5.61% |
| 5 | Communication Services | 3.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2051
CALL
Glaukos
GKOS
$14.5B
| $4.89M | ﹤0.01% |
+29,800
| New | +$4.99M |
2026 Q3
0 quarters
|
|
2052
LandBridge Corporation
LB
$2.17B
| $4.88M | ﹤0.01% |
60,179
+1,550
| +3% | +$126K |
2024 Q4
7 quarters
|
|
2053
GSK
GSK
$101B
| $4.88M | ﹤0.01% |
101,265
+72,408
| +251% | +$3.7M |
2013 Q2
53 quarters
|
|
2054
Aquestive Therapeutics
AQST
$491M
| $4.87M | ﹤0.01% |
1,051,639
+54,974
| +6% | +$244K |
2024 Q2
9 quarters
|
|
2055
PUT
Carvana
CVNA
$79.8B
| $4.87M | ﹤0.01% |
+77,800
| New | +$5.33M |
2026 Q3
0 quarters
|
|
2056
McGrath RentCorp
MGRC
$3.14B
| $4.86M | ﹤0.01% |
42,492
+21,159
| +99% | +$2.45M |
2016 Q1
42 quarters
|
|
2057
Match Group
MTCH
$9.47B
| $4.86M | ﹤0.01% |
120,975
-474,088
| -80% | -$19M |
2022 Q1
18 quarters
|
|
2058
Procept Biorobotics
PRCT
$1.37B
| $4.85M | ﹤0.01% |
266,458
+103,102
| +63% | +$2.06M |
2022 Q1
18 quarters
|
|
2059
Exponent
EXPO
$4.15B
| $4.83M | ﹤0.01% |
73,851
+9,030
| +14% | +$597K |
2016 Q2
41 quarters
|
|
2060
AMERISAFE
AMSF
$361M
| $4.83M | ﹤0.01% |
204,440
+99,244
| +94% | +$2.82M |
2016 Q3
40 quarters
|
|
2061
Fortrea Holdings
FTRE
$1.95B
| $4.83M | ﹤0.01% |
242,091
+44,454
| +22% | +$824K |
2023 Q3
12 quarters
|
|
2062
Riot Platforms
RIOT
$6.57B
| $4.82M | ﹤0.01% |
239,420
-224,130
| -48% | -$4.72M |
2021 Q1
22 quarters
|
|
2063
SLM Corp
SLM
$3.23B
| $4.82M | ﹤0.01% |
212,856
+180,922
| +567% | +$4.66M |
2013 Q2
53 quarters
|
|
2064
PUT
ImmunityBio
IBRX
$6.4B
| $4.81M | ﹤0.01% |
+510,000
| New | +$4.08M |
2026 Q3
0 quarters
|
|
2065
Ligand Pharmaceuticals
LGND
$6.18B
| $4.76M | ﹤0.01% |
15,252
+8,525
| +127% | +$2.52M |
2013 Q2
53 quarters
|
|
2066
AMC Global Media
AMCX
$391M
| $4.73M | ﹤0.01% |
405,970
+8,197
| +2% | +$93.8K |
2013 Q2
53 quarters
|
|
2067
Addus HomeCare
ADUS
$2.29B
| $4.73M | ﹤0.01% |
42,810
+8,111
| +23% | +$933K |
2013 Q2
53 quarters
|
|
2068
Yeti Holdings
YETI
$2.87B
| $4.73M | ﹤0.01% |
115,320
+74,681
| +184% | +$3.43M |
2019 Q1
30 quarters
|
|
2069
Ashland
ASH
$3.5B
| $4.71M | ﹤0.01% |
69,341
+43,900
| +173% | +$3.1M |
2013 Q2
53 quarters
|
|
2070
CALL
Canadian Natural Resources
CNQ
$101B
| $4.71M | ﹤0.01% |
100,000
| – | – |
2024 Q4
7 quarters
|
|
|
2071
PUT
Canadian Natural Resources
CNQ
$101B
| $4.71M | ﹤0.01% |
100,000
| – | – |
2024 Q4
7 quarters
|
|
2072
Solid Power
SLDP
$403M
| $4.69M | ﹤0.01% |
1,976,636
+900,432
| +84% | +$2.11M |
2022 Q1
18 quarters
|
|
2073
Kilroy Realty
KRC
$4.19B
| $4.69M | ﹤0.01% |
141,084
+61,950
| +78% | +$2.3M |
2013 Q2
53 quarters
|
|
2074
IPG Photonics
IPGP
$2.88B
| $4.69M | ﹤0.01% |
59,938
+47,862
| +396% | +$4.13M |
2013 Q2
53 quarters
|
|
2075
Methanex
MEOH
$5.45B
| $4.66M | ﹤0.01% |
79,351
+38,250
| +93% | +$2.15M |
2013 Q2
53 quarters
|
|
Similar funds
Barclays's Q3 2026 Portfolio in Review
As of Q3 2026, Barclays held 5,855 positions worth $500B, down 4% from $521B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Barclays withdrew a net $19B in Q3 2026, closing 474 positions and reducing 1,494 holdings. Its most notable exit was ExxonMobil, an estimated $761M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 49% of assets, down from 55% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Barclays opened a new position in iShares Broad USD High Yield Corporate Bond ETF worth $199M.
- Barclays's largest Q3 2026 buy was iShares Broad USD High Yield Corporate Bond ETF: 5,582,517 shares worth $199M.
- Barclays added most to Tesla in Q3 2026, an estimated $17.5B increase.
- Barclays's biggest Q3 2026 reduction was iShares MSCI Emerging Markets ETF, cutting an estimated $35.8B.
- Barclays fully exited ExxonMobil in Q3 2026, selling an estimated $761M.
- Barclays's ten largest holdings make up 40% of its $500B portfolio in Q3 2026.
- Barclays opened 525 new positions and closed 474 in Q3 2026.
- Barclays's portfolio value fell 4% quarter-over-quarter to $500B.
Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.